27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- The FDA has approved ADMA Biologics Inc's (NASDAQ:ADMA) in-house aseptic fill-finish machine, the VanRx SA25.
- Related Content: ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility.
- With the VanRx operational, the Company expects a meaningful improvement in gross margins, enhanced patient supply consistency, accelerated inventory production cycle times, and increased control and visibility of commercial product lot releases.
- The approval of the VanRx will also provide ADMA with the opportunity to onboard new fill-finish contract manufacturing opportunities with third parties.
- The VanRx fill-finish machine utilizes a closed isolator design that removes human interventions and provides safe drug products for patients.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: ADMA shares are up 10.2% at $1.40 during the premarket session on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!